FDA Clearance Tracker · K241232
Galen Second Read
Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Jan 24, 2025
Substantially Equivalent
Time to decision
267 days
Received May 2, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K241232
- Device name
- Galen Second Read
- Applicant
- Ibex Medical Analytics , Ltd.
- Applicant location
- Tel Aviv, IL
- Received
- May 2, 2024
- Decided
- Jan 24, 2025
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 864.3750
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QPN. The earliest in FDA's data is DEN200080, decided Sep 21, 2021.
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
- FDA database record for K241232
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Ibex Medical Analytics , Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.